Novo Nordisk CEO says firm's obesity pill could launch before Eli Lilly
Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral weight loss candidate.
▶︎
Eli Lilly CEO Dave Ricks on revolutionizing healthcare and medicine
▶︎
Brødrene Pedersen - Historien om Novo: Afsnit 1 - “Det kan De da ikke”
▶︎
Novo Nordisk CEO Lars Jorgensen testifies before Senate on weight loss drugs pricing — 9/24/24
▶︎
'Attractive' growth ahead for Novo Nordisk, CEO says
▶︎
Access Middle East - 06-Jul-26
▶︎
Senate HELP Hearing (9/24/24) - Novo Nordisk Hearing
▶︎
West Texas Land is Perfect for Data Centers, Says LandBridge Founder
▶︎
Ozempic maker testifies about weight loss drug prices during Senate hearing | full video
▶︎
Holcim CEO: Concrete, AI and Europe's Housing Crisis | Podcast | In Good Company
▶︎
How Eli Lilly Became a $1 Trillion Company
▶︎
Novo Nordisk CEO on Wegovy, Ozempic, Profit Forecast, US Market
▶︎
The CEO Behind Ozempic, Wegovy and Europe's Most Valuable Company
▶︎
When Animals Surprise Photographers in the Sweetest Way! 😍
▶︎
Qantas’ 22 Hour Flights - Why Gulf Carriers Are Weirdly Nervous
▶︎
AI Bubble Will Burst Eventually Says Bridgewater's Ray Dalio
▶︎
The Mitochondria Doctor: This Reverses Gray Hair, Makes You Feel Young Again & Fixes Disease!
▶︎
Eli Lilly CEO David Ricks on Q1 results, weight loss drug competition and status of weight-loss pill
▶︎
Germany just hit the point of no return - Yanis Varoufakis & Wolfgang Munchau | The Econoclasts
▶︎
Wie Novo Nordisk zum wertvollsten Unternehmen Europas wurde
▶︎